CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Q32 Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Q32 Bio Inc
830 Winter Street, 2nd Floor
Phone: (781) 301-7277p:781 301-7277 WALTHAM, MA  02451  United States Ticker: QTTBQTTB

Business Summary
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
(Source: PRESS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board Arthur O.Tzianabos 60 9/6/2022 4/1/2016
President, Chief Operating Officer, Company Secretary Paul G.Alloway 52 11/17/2023 5/1/2020
Principal Financial Officer, Principal Accounting Officer, Vice President, Corporate Controller, Tr CharlesMichaud 56 11/17/2023 11/17/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
FIXX
HOMOLOGY MEDICINES INC
Homology Medicines Security Corporation
Legacy Q32
Q32 BIO INCvQ32 Bio Inc.
QTTB

General Information
Number of Employees: 7 (As of 12/31/2023)
Outstanding Shares: 11,963,142 (As of 3/26/2024)
Shareholders: 14
Stock Exchange: NASD
Federal Tax Id: 473468154
Fax Number: (302) 655-5049
Email Address: info@homologymedicines.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024